OPKO Health (NASDAQ:OPK) Stock Rating Raised to Outperform at Barrington Research

Key Points

• Barrington Research upgraded OPKO Health to “outperform” from “market perform” and set a $2.25 price target, implying approximately 39.75% upside from the reported $1.61 share price.
• Analyst sentiment is generally positive, with MarketBeat reporting a “Moderate Buy” consensus rating and a $1.93 average target price, despite one “sell” rating.
• OPKO’s latest quarterly results exceeded expectations, with an adjusted loss of $0.01 per share versus the $0.08 expected loss and revenue of $163.58 million, up 4.3% year over year. Separately, Labcorp’s planned acquisition of BioReference assets for up to $872 million could strengthen OPKO’s balance sheet and support a greater focus on biopharmaceuticals.

OPKO Health (NASDAQ:OPK - Get Free Report) was upgraded by analysts at Barrington Research from a "market perform" rating to an "outperform" rating in a note issued to investors on Friday, Marketbeat reports. The brokerage currently has a $2.25 price objective on the biotechnology company's stock. Barrington Research's target price indicates a potential upside of 39.75% from the company's current price.

Several other equities research analysts have also weighed in on the stock. HC Wainwright reiterated a "buy" rating on shares of OPKO Health in a report on Wednesday, July 29th. Zacks Research raised OPKO Health from a "hold" rating to a "strong-buy" rating in a research note on Monday, September 28th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of OPKO Health in a report on Thursday, August 13th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, OPKO Health has a consensus rating of "Moderate Buy" and a consensus target price of $1.93.

OPKO Health Stock Performance

Shares of OPK stock opened at $1.61 on Friday. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.35 and a quick ratio of 2.93. The stock has a market cap of $1.20 billion, a PE ratio of -17.89 and a beta of 1.51. The stock has a 50-day moving average of $1.52 and a 200-day moving average of $1.37. OPKO Health has a one year low of $0.98 and a one year high of $1.75.

OPKO Health (NASDAQ:OPK - Get Free Report) last announced its quarterly earnings results on Monday, July 27th. The biotechnology company reported ($0.01) earnings per share for the quarter, beating analysts' consensus estimates of ($0.08) by $0.07. The business had revenue of $163.58 million for the quarter, compared to the consensus estimate of $131.23 million. OPKO Health had a negative net margin of 12.40% and a negative return on equity of 5.88%. OPKO Health's revenue for the quarter was up 4.3% on a year-over-year basis. During the same period last year, the company posted ($0.19) EPS. As a group, sell-side analysts expect that OPKO Health will post -0.23 earnings per share for the current year.

Hedge Funds Weigh In On OPKO Health

A number of institutional investors and hedge funds have recently added to or reduced their stakes in OPK. Two Sigma Securities LLC bought a new position in shares of OPKO Health during the second quarter worth about $27,000. World Investment Advisors raised its position in OPKO Health by 63.8% in the 4th quarter. World Investment Advisors now owns 66,520 shares of the biotechnology company's stock valued at $84,000 after buying an additional 25,902 shares during the last quarter. Apella Capital LLC bought a new stake in OPKO Health in the 1st quarter valued at approximately $34,000. EP Wealth Advisors LLC acquired a new position in OPKO Health during the 2nd quarter worth approximately $45,000. Finally, Diversify Advisory Services LLC bought a new position in shares of OPKO Health during the 2nd quarter worth approximately $37,000. 64.63% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting OPKO Health

Here are the key news stories impacting OPKO Health this week:

• Positive Sentiment: Labcorp will acquire the BioReference assets for $722 million in cash, with total consideration potentially reaching $872 million. The proceeds could strengthen OPKO’s balance sheet, improve financial flexibility and help fund its biopharma pipeline. Labcorp and OPKO transaction announcement
• Positive Sentiment: The assets being sold include specialty testing services in women’s health and BioReference’s prostate cancer risk-assessment test, expanding Labcorp’s clinical testing platform while monetizing businesses for OPKO. Labcorp BioReference asset details
• Positive Sentiment: The deal represents a strategic shift for OPKO toward its biopharmaceutical business, which investors may view as a potentially higher-growth focus than operating a broad clinical laboratory unit. OPKO refocuses on biopharma
• Neutral Sentiment: The transaction remains subject to customary closing conditions, and the final proceeds may depend on the deal’s structure and contingent payments. Investors will likely monitor how OPKO allocates the cash and whether the sale affects BioReference-related revenue and earnings.

About OPKO Health

OPKO Health, Inc is a healthcare company focused on diagnostics and pharmaceuticals. Through its diagnostics businesses, the company provides laboratory services and specialized tests intended to support the detection, diagnosis and management of disease. Its operations include BioReference Health, a clinical laboratory business serving physicians, hospitals, employers and patients, as well as the 4Kscore test, which helps assess the risk of aggressive prostate cancer.

OPKO's pharmaceutical business develops and commercializes treatments for conditions including kidney disease, endocrine disorders and growth-related conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.